Although anti–TNF-α therapies are highly effective in rheumatoid arthritis [127,129], they have consistently failed to improve glycemic control or body weight in obesity and type 2 diabetes [128,129,132]. This evidence concerns the gene TNF and type 2 diabetes mellitus.